EQIPD VIRTUAL WORKSHOP - Rigor, reproducibility and data management in nonclinical research
THE AIM of this workshop is to give participants theoretical knowledge and practical insights on factors that contribute to poor research reproducibility and replicability, and how to improve the trustworthiness and quality of research. The event is intended for researchers/students in the field of life sciences.
DATE and TIME: April 21, 10:00-13:00 (Helsinki time)
PLACE: Online (link will be sent to registered e-mail).
REGISTRATION to Workshop is open until April 19th, 14:00 (Helsinki time): https://elomake.helsinki.fi/lomakkeet/110835/lomake.html
The participation is free of charge; however, registration is necessary (certificates of participation will be send to the registered e-mail address upon request).
10:00-10:40 Malcolm Macleod (University of Edinburgh): Why changes in research practice are needed NOW and one cannot wait until tomorrow? Discussion: What prevents the participants from changing?
10:40-11:20 Thomas Steckler (Janssen Pharmaceutica NV): The need to recognize “research conducted with sufficient rigor” Discussion: What prevents the participants from applying blinding, randomization, etc?
11:30-12:10 Sami Virtanen (Orion Pharma): Rigor in data management. Discussion: Can I trace raw data from a publication?
12:10-12:50 Anton Bespalov & Valentina Vengeliene (PAASP GmbH): Rigor in collaborative research. Discussion: Do workshop participants have experience with collaborative research?
12:50-13:00 Vootele Voikar (Neuroscience Center, HiLIFE), Andreas Scherer (Institute for Molecular Medicine Finland, HiLIFE): Do we need a Reproducibility Network in Finland?
ORGANISERS: Neuroscience Center (NC), Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, European Infrastructure for Translational Medicine (EATRIS), Partnership for Assessment and Accreditation of Scientific Practice (PAASP), Enhancing Quality in Preclinical Data (EQIPD) consortium supported through the European Union’s Innovative Medicines Initiative (IMI).